Putting the immune system in control

DCprime is the front-runner in the field of relapse vaccines, a new class of oncology vaccines administered after standard of care therapy to delay or prevent disease recurrence. Relapse vaccines are aimed at improving survival by putting the patient’s immune system back in control while tumor burden is low, and the immune system is in relatively good shape.

Read More

A growing pipeline of relapse vaccines

Our lead product DCP-001 is a cell-based vaccine addressing blood cancers with a high risk of relapse. DCP-001 is currently being evaluated in a Phase II clinical trial in acute myeloid leukemia (AML). We are pursuing similar vaccination approaches in other malignancies, including solid tumors.

Read More

Latest News

DCprime and Glycotope Sign Licensing Agreement to Advance Program Combining Cancer Vaccination and Therapeutic Antibody Platforms

Leiden, The Netherlands, and Berlin, Germany, September 21, 2020 – DCprime, the front-runner in the field of relapse vaccines, and Glycotope GmbH, a clinical-stage oncology/immuno-oncology company built on world-leading glycobiology expertise, today announced an expansion of their existing partnership through a new research collaboration and licensing agreement. Originally initiated in

Read More »

DCprime and PCI Biotech Announce a Research Collaboration to Explore Novel Cancer Vaccination Concepts

Leiden, The Netherlands and Oslo, Norway, September, 1st 2020 – DCprime, the front-runner in the field of relapse vaccines, and PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology via PhotoChemical Internalisation, today announced an extensive research collaboration. Within the collaboration, DCprime and PCI Biotech

Read More »

Latest News